NMR: Drug Discovery and Design-Post Genomic Analysis
	Cambridge Healthtech Institute , McLean, Virginia October 24-26, 2000
	Nuclear magnetic resonance has been a powerful tool for characterizing the structures of organic and biochemical compounds. Advances in protein NMR continue to push forward the boundaries of biomolecular analysis, with recent breakthroughs for membrane proteins. The past year has seen significant advances in NMR analysis from a broad array of disciplines - progress in the size of systems to be studied and the accuracy with which structures can be determined. Solid-state NMR is undergoing rapid expansion, and rational design of high-affinity ligands and screening of synthetic and natural molecular libraries are increasingly realistic goals. NMR is both a complementary technology to X-ray crystallography and an important tool on its own.
	Organized by:	Cambridge Healthtech Institute
	Invited Speakers:	NMR and Drug Screening Improved Methods for NMR Screening: Dr. Claudio Dalvit, Pharmacia S.p.A. STD NMR to Screen Libraries and to Characterize Binding: Dr. Bernd Meyer, Universität Hamburg Library Design for NMR-Based Screening: Dr. Christopher Lepre, Vertex Pharmaceuticals, Inc. Automation of NMR Measurements and Data Evaluation for Systematically Screening Interactions of Small Molecules with Target Proteins: Dr. Alfred Ross, Hoffmann-La Roche Ltd. Structure-Based Screening in Target Selection, Hit Generation, and Lead Optimization: Dr. Mats Wikström, Pharmacia Corporation NMR in Drug Discovery and Development Designing and Screening Small Molecules That Target RNA Using Fluorescence and NMR Spectroscopy: Dr. John P. Marino, National Institute of Standards and Technology NMR-Based Metabonomic Approaches to Drug Toxicity Evaluation: Dr. Jeremy K. Nicholson, University of London The Role of NMR in Drug Development: Dr. John Shockcor, Dupont Pharmaceuticals LC-NMR-MS: The Optimal Analytical Tool for Structure Confirmation and Identification: Dr. Mark O’Neil-Johnson, Bruker Instruments, Inc. Targeting RNA: The Next Generation: Dr. James R. Williamson, Scripps Research Institute NMR and Biological Targets Use of Molecular Alignment in Small Molecule/Protein Interactions: Dr. James H. Prestegard, University of Georgia Structural Biology of Hepatocyte Growth Factor: Mechanisms and Views to Agonists and Antagonists: Dr. R. Andrew Byrd, National Cancer Institute–FCRDC Solid-State NMR to Resolve Structural Details of Ligands at Their Site of Action in Membrane-Bound Targets: Dr. David Middleton, University of Manchester Structural Studies of ICEBERG: An Inhibitor Caspase-1 Activation: Dr. Wayne Fairbrother, Genentech, Inc. Automated NMR Structure Calculation by Network-Anchored Assignment and Constraint Combination: Dr. Peter Guntert, Institute for Molecular Biology and Biophysics, ETH [tentative] Protein Structure Determination Structural Proteomics: Methods of Target Validation and Invalidation: Dr. Aled Edwards, University of Toronto and Chalon Biotechnology Protein Secondary Structure Studies by FTIR Spectroscopy: Dr. Yijia Jiang, Amgen Inc. Proteins and Powder Diffraction: Dr. R. B. Von Dreele, Los Alamos National Laboratory Three-Dimensional Structure of the G-Protein Coupled Receptor, Rhodopsin: Dr. P. L. Yeagle, University of Connecticut Structure Determination by Synchrotron: Dr. Andreij Leukemiac, University of Oregon (invited)
	Deadline for Abstracts:	September 22, 2000
	Registration:	Available on-line
	Email for Requests and Registration:	jlaakso@healthtech.com
	Posted by: Jennifer Laakso   Host: wks217.healthtech.com date: June 29, 2000 17:11:08 Generated by meetings and positions 2.0 by Kai Garlipp Logo and Logo Images by Art for BioMed / Syrinx GmbH - Frankfurt / Germany. 4.1 (c) 1995-99 HUM-MOLGEN. All rights reserved. Liability and Copyright.